Want to see SE:XBRANE full AI Analyst Report?
XBRANE Stock Chart & Stats
kr10.37
>-kr0.01(-2.10%)
At close: 4:00 PM EST
kr10.37
>-kr0.01(-2.10%)
Day’s Range― - ―
52-Week Rangekr5.42 - kr35.00
Previous CloseN/A
Volume1.93M
Average Volume (3M)36.69K
Market Cap
kr278.17M
Enterprise Valuekr232.63M
Total Cash (Recent Filing)kr49.50M
Total Debt (Recent Filing)kr63.71M
Price to Earnings (P/E)―
Beta0.60
Next Earnings
Oct 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.40
Shares Outstanding20,605,349
10 Day Avg. Volume62,395
30 Day Avg. Volume36,694
Financial Highlights & Ratios
PEG Ratio-1.22
Price to Book (P/B)27.69
Price to Sales (P/S)101.88
P/FCF Ratio-39.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.94
Revenue Forecast (FY)kr180.00M
Bulls Say, Bears Say
Bulls Say
Low Leverage And Substantial EquityLow leverage gives Xbrane more financial flexibility than a highly indebted biotech, while its substantial equity base provides support for ongoing development and commercialization. This balance-sheet position can help the company manage volatility and pursue partnerships without immediate dependence on heavy borrowing.
Biosimilar-focused Business ModelA focus on biosimilars targets established biologic markets with lower-cost alternatives, creating a structurally relevant opportunity as healthcare systems seek savings. Xbrane’s development and commercialization capabilities provide a defined platform for building products and competing in this expanding segment.
Multiple Partnering Revenue ChannelsThe partnering model can diversify how Xbrane captures value from its pipeline, allowing partners to fund or execute parts of development, regulatory work, manufacturing and commercialization. Upfronts, milestones and royalties can reduce the need to finance every activity independently.
Bears Say
Persistent Cash BurnOngoing negative operating and free cash flow means Xbrane is not yet funding its activities internally. Continued cash consumption can require additional financing or use of balance-sheet capacity, limiting strategic flexibility and increasing the importance of successful launches, approvals and partnerships.
Operating Losses And Weak ProfitabilityThe core business is still not covering operating costs, while negative TTM gross profit indicates that recent revenue has not translated into healthy product economics. Persistent losses can erode equity over time and make sustainable growth dependent on operational improvement or external funding.
Volatile And Declining Revenue TrendRecent TTM growth has not established a consistent upward trajectory because annual revenue fell materially in both 2024 and 2025. This volatility makes planning and resource allocation more difficult and raises uncertainty about the durability of commercial demand and product contributions.
Xbrane Biopharma AB News
XBRANE FAQ
What was Xbrane Biopharma AB’s price range in the past 12 months?
Xbrane Biopharma AB lowest stock price was kr5.42 and its highest was kr35.00 in the past 12 months.
What is Xbrane Biopharma AB’s market cap?
Xbrane Biopharma AB’s market cap is kr278.17M.
When is Xbrane Biopharma AB’s upcoming earnings report date?
Xbrane Biopharma AB’s upcoming earnings report date is Oct 30, 2026 which is in 21 days.
How were Xbrane Biopharma AB’s earnings last quarter?
Xbrane Biopharma AB released its earnings results on Jul 17, 2026. The company reported -kr0.554 earnings per share for the quarter.
Is Xbrane Biopharma AB overvalued?
According to Wall Street analysts Xbrane Biopharma AB’s price is currently Overvalued.
Does Xbrane Biopharma AB pay dividends?
Xbrane Biopharma AB does not currently pay dividends.
What is Xbrane Biopharma AB’s EPS estimate?
Xbrane Biopharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Xbrane Biopharma AB have?
Xbrane Biopharma AB has 20,605,349 shares outstanding.
What happened to Xbrane Biopharma AB’s price movement after its last earnings report?
Xbrane Biopharma AB reported an EPS of -kr0.554 in its last earnings report. Following the earnings report the stock price went down -0.935%.
Which hedge fund is a major shareholder of Xbrane Biopharma AB?
Currently, no hedge funds are holding shares in SE:XBRANE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xbrane Biopharma AB
Xbrane Biopharma AB (publ) is a biotechnology firm, founded in 2008 and based in Solna, Sweden, that specializes in the creation, manufacturing, and distribution of biosimilar medications. The company's development pipeline includes Xlucane, a ranibizumab biosimilar presently undergoing pivotal Phase III clinical trials. This therapeutic candidate is being evaluated for the treatment of several serious eye conditions, including wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion. In its earlier, preclinical stages, Xbrane is progressing a range of biosimilars: Xcimzane: Targeting autoimmune diseases such as rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, psoriasis, and Crohn's disease. Xoncane: Designed for acute lymphocytic leukemia. Spherotide: Intended for prostate cancer, breast cancer, endometriosis, and uterine myoma. Xdivane: Developed for various cancers, including melanoma, lung cancer, head and throat cancer, bladder cancer, urinary tract cancer, and renal cell carcinoma. Moreover, Xbrane has established a strategic partnership with STADA Arzneimittel AG. This collaboration aims to explore and potentially pursue joint development and commercialization opportunities for its preclinical biosimilar candidates, Xcimzane and Xdivane.
Technical Analysis
Hansa Biopharma AB
―
Alligator Bioscience AB
―
BioInvent International AB
―
Elicera Therapeutics AB
―
Cantargia AB
―